10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2012

¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from _________ to ________

Commission file numbers 000-32141

NUTRA PHARMA CORP.

(Name of registrant as specified in its charter)

California	91-2021600
(State or Other Jurisdiction of Organization)	(IRS Employer Identification Number)

2776 University Drive, Coral Springs, Florida	33065
(Address of principal executive offices)	(Zip Code)

(954) 509-0911

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yesþ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 

Yes ¨ No þ

The number of shares outstanding of the registrant's common stock, par value $0.001 per share, as of November 26, 2012 there were 522,134,676 shares of common stock.

Explanatory Note

The purpose of this Amendment No. 1 to Nutra Pharma Corporation's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on December 5, 2012 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. This report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

Pursuant to Rule 406T of Regulation S-T, the interactive data files on this report hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

Item 6. Exhibits

Exhibit No.	Title
31.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101 - Interactive data files pursuant to Rule 405 of Regulation S-T, as follows:

101.INS -       XBRL Instance Document

101.SCH -      XBRL Taxonomy Extension Schema Document

101.CAL -      XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF -       XBRL Taxonomy Extension Definition Linkbase Document

101.LAB -      XBRL Taxonomy Extension Label Linkbase Document

101.PRE -      XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NUTRA PHARMA CORP.
	Registrant
Dated:  December 12, 2012	/s/ Rik J. Deitsch
	Rik J. Deitsch
	Chief Executive Officer/Chief Financial Officer

EX-31.1

NUTRA PHARMA CORP.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

I, Rik Deitsch, the Chief Executive Officer and Chief Financial Officer of Nutra Pharma Corp., certify that:

1. I have reviewed this quarterly report on Form 10-Q  of Nutra Pharma Corp.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Small Business Issuer as of, and for, the periods presented in this quarterly report;

4. The Small Business Issuer's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Small Business Issuer and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) [Omitted pursuant to SEC Release No. 33-8238];

(c) Evaluated the effectiveness of the Small Business Issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Small Business Issuer’s internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and

5. The Small Business Issuer’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors of the small business issuer's board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Dated: December 12, 2012

/s/ Rik J. Deitsch

Rik J. Deitsch

Chief Executive Officer/Chief Financial Officer

EX-32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Nutra Pharma Corp., (the "Company") on Form 10-Q for the quarterly period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Rik Deitsch, the Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 12, 2012

/s/ Rik J. Deitsch

Rik J. Deitsch

Chief Executive Officer and Chief Financial Officer

XML

SUBSEQUENT EVENTS (Details Textual) (Investor [Member], USD $)	9 Months Ended
	Sep. 30, 2012
Investor [Member]
Common Stock Price Per Share (in dollars per share)	$ 0.01
Warrants To Purchase Common Stock Per Share Value (in dollars per share)	$ 0.1
Investment Warrants Expiration Date	Dec. 13, 2014

XML

STOCK OPTIONS AND WARRANTS (Details) (Stock Option [Member], USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Stock Option [Member]
Number of shares, Begining Balance	0	1,000,000
Number of shares, Exercised	0	0
Number of shares, Issued	0	0
Number of shares, Forfeited	0	(1,000,000)
Number of shares, Ending Balance	0	0
Weighted average exercise price, Begining Balance (in dollars per share)	$ 0	$ 0.2
Weighted average exercise price, Exercised (in dollars per share)	$ 0	$ 0
Weighted average exercise price, Issued (in dollars per share)	$ 0	$ 0
Weighted average exercise price, Forfeited (in dollars per share)	$ 0	$ 0.2
Weighted average exercise price, Ending Balance (in dollars per share)	$ 0	$ 0

XML

FAIR VALUE MEASUREMENTS (Details 3) (USD $)	9 Months Ended		12 Months Ended		9 Months Ended
	Sep. 30, 2012		Dec. 31, 2011		Sep. 30, 2012 Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2011 Fair Value, Inputs, Level 3 [Member]
Beginning balance	$ 206,863	[1]			$ 206,863	$ 109,500
Purchases, issuances, and settlements	0		0		368,648	0
Day one loss on value of hybrid instrument					314,896	0
(Gain) loss from change in fair value					(5,967)	(26,667)
Conversion to common stock					(489,420)	0
Ending balance	$ 395,020	[1]	$ 206,863	[1]	$ 395,020	$ 82,833

[1] Convertible Notes - At Fair Value: Convertible Note Payable Dated October 27, 2011 at Fair Value - On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $105,361 and $120,044. Convertible Note Payable Dated December 5, 2011 at Fair Value - On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $74,548 and $86,819.During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares at $0.005 per share. Convertible Note Payable Dated February 3, 2012 at Fair Value - On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the Set Price"). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company at the recent low bid of $0.007 per share, providing 7,500,000 (seven million, five hundred thousand) shares of Nutra Pharma common stock to relinquish the total debt of $52,500.At September 30, 2012, this convertible note payable, at fair value, was recorded at $109,386. Convertible Note Payable Dated March 16, 2012 at Fair Value - On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the "conversion price"). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.At September 30, 2012, this convertible note payable, at fair value, was recorded at $105,725.The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $100,914 and $103,244, respectively at September 30, 2012 and December 31, 2011 related to the recognition of (i) the hybrid note and (ii) the derivative instrument arising from the fair value measurement due to the fair value of the hybrid note and embedded derivative exceeding the proceeds that the Company received from the arrangement. Therefore, the Company was required to record a loss on the derivative financial instrument. In addition, the fair value will change in future periods, based upon changes in the Company’s common stock price and changes in other assumptions and market indicators used in the valuation techniques. These future changes will be currently recognized in other expense or other income on the Company’s statement of operations. Accordingly, the Company recognized the change in fair value of derivative in the amount of $27,756 and $13,119 during the nine months ended September 30, 2012 and the year of 2011.The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock

XML

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	12 Months Ended			1 Months Ended	9 Months Ended	12 Months Ended			9 Months Ended
	Dec. 31, 2010 Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. [Member]	Dec. 31, 2008 Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. [Member]	Dec. 31, 2006 Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. [Member]	Jan. 31, 2012 Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch [Member]	Sep. 30, 2012 Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch [Member]	Dec. 31, 2011 Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch [Member]	Dec. 31, 2011 Laurence N. Raymond v. Receptopharm, Inc. et al. [Member]	Dec. 31, 2011 Paul F. Reid v, Harold H. Rumph et al. [Member]	Sep. 30, 2012 Dustin Travers v, XenaCare Holdings, Inc., et al. [Member]	Sep. 30, 2012 Involuntary Petition of Bankruptcy [Member]	Sep. 30, 2012 Shelter Developers of America vs. ReceptoPharm, Inc. [Member]
Loss Contingency, Damages Sought, Value		$ 768,506	$ 118,928.15			$ 500,000	$ 300,000	$ 330,000		$ 990,927.75
Cancellation Of Share Certificate (in shares)	1,214,800
Potential Exposure	10,000,000
Additional Shares Claimed (in shares)	1,214,800
Alleged Shares Claimed (in shares)	1,750,000
Reimbursement Expenses For Third Party						359,826.85
Component Agreed Price						350,000
Component Agreed Price Period						7 months
Component Agreed Price Monthly Installments						50,000
Loss Contingency Stock Value						400,000
Loss Contingency, Damages Paid, Value				25,000		150,000					38,934.9
Loss Contingency Late Fee						5,000
Loss Contingency Damages Paid Value Total						205,000
Loss Contingency Additional Payments Agreed					15,000	10,000
Loss Contingency Accrual, at Carrying Value					175,000
Loss Contingency Damages Due Monthly					30,000
Loss Contingency, Damages Awarded, Value					450,000				16,500
Loss Contingency Claim Amount								140,000
Loss Contingency Damages Awarded Value Monthly Installment									2,750
Loss Contingency Damages Sought Amended Value										$ 816,662.39
Loss Contingency Damages Awarded Value Monthly Installment Number									6

XML

DUE TO OFFICERS

9 Months Ended

Sep. 30, 2012

Due To Officers [Abstract]

Due To Officers [Text Block]

4. DUE TO OFFICERS

At September 30, 2012 and December 31, 2011, the balance due to officers consisted of the following:

	September 30, 2012		December 31, 2011
An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at September 30, 2012 and December 31, 2011, respectively, includes accrued interest payable of $317,790 and $297,980.	$	725,464	$	738,993
A loan from Paul Reid, the President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero interest rate at September 30, 2012 and December 31, 2011.		115,759		111,536
Ending balances	$	841,223	$	850,529

During the nine months ended September 30, 2012, we borrowed $151,138 from and repaid $9,478 to Mr. Deitsch. In addition, Mr. Deitsch assigned $175,000 of the debt to a third party on January 2, 2012.

XML

DUE TO OFFICERS (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Management [Member]	Dec. 31, 2011 Management [Member]	Sep. 30, 2012 President [Member]	Dec. 31, 2011 President [Member]
Debt Instrument, Interest Rate, Stated Percentage			4.00%	4.00%	5.00%	5.00%
Interest Payable			$ 317,790	$ 297,980
Proceeds From Related Party Debt	151,138	613,720	151,138
Repayments Of Related Party Debt	9,478	688,425	9,478
Amount Of Debt Assigned To Third Party Total			$ 175,000

XML

DUE TO OFFICERS (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Due to officers	$ 841,223	$ 850,529
Management [Member]
Due to officers	725,464	738,993
President [Member]
Due to officers	$ 115,759	$ 111,536

XML

OTHER DEBT (Details) (USD $)	Sep. 30, 2012		Dec. 31, 2011
Note payable - Related Party	$ 190,000	[1]	$ 200,000	[1]
Notes payable - Non Related Parties	879,000	[2]	805,000	[2]
Convertible notes payable, at fair value	395,020	[3]	206,863	[3]
Other debt	$ 1,464,020		$ 1,211,863

[1] During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 during the third quarter of 2012. Under the terms of the loan agreement this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At September 30, 2012 and December 31, 2011, we owed this director accrued interest of $78,259 and $54,423, respectively.

[2] At September 30, 2012, the balance consisted of the following loans: · In May 2011, the Company received two loans for a total of $50,000 from non-related parties. These loans were expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. These loans are guaranteed by an officer of the Company. The Company was unable to repay the loans and they continue to accrue interest. At September 30, 2012 and December 31, 2011, the accrued interest payable was $14,417 and $8,899, respectively. · In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans was to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 5 days. The Company will also issue a total of 4,000,000 restricted shares to the note holders per the amendment. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At September 30, 2012 and December 31, 2011, the accrued interest was $6,666 at each period end. · On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. ("LPR"), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement whereunder we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment).The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company's free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during the quarter ended March 31, 2012. On June 11, 2012, LPR sold the note to Southridge Partners, LLP ("Southridge"). Once the debt is satisfied, LPR will return all of the Company's collateral shares currently held by LPR's attorney. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt. The balance due LPR at September 30, 2012 is $250,000. · On March 22, 2012 the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000. $25,000 of the funds was received during the first quarter of 2012. The remaining amount of $50,000 was received during the third quarter of 2012. The note is due and payable on the date that is six months from the execution and funding of the note. Interest is based on a rate of three (3%) percent per month to be accrued from the later of the date of the note or receipt of funds until all principal has been paid. In August 2012, McDonald Trust sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt. · On March 26, 2012, the Company issued a promissory note to Southridge Partners II, LP in the amount of $4,000. The term of the note was 45 days and bears a flat interest of $500. On October 26, 2012 Southridge converted the note into 497,238 shares of restricted common stock in full satisfaction of the note.

[3] Convertible Notes - At Fair Value: Convertible Note Payable Dated October 27, 2011 at Fair Value - On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $105,361 and $120,044. Convertible Note Payable Dated December 5, 2011 at Fair Value - On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $74,548 and $86,819.During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares at $0.005 per share. Convertible Note Payable Dated February 3, 2012 at Fair Value - On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the Set Price"). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company at the recent low bid of $0.007 per share, providing 7,500,000 (seven million, five hundred thousand) shares of Nutra Pharma common stock to relinquish the total debt of $52,500.At September 30, 2012, this convertible note payable, at fair value, was recorded at $109,386. Convertible Note Payable Dated March 16, 2012 at Fair Value - On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the "conversion price"). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.At September 30, 2012, this convertible note payable, at fair value, was recorded at $105,725.The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $100,914 and $103,244, respectively at September 30, 2012 and December 31, 2011 related to the recognition of (i) the hybrid note and (ii) the derivative instrument arising from the fair value measurement due to the fair value of the hybrid note and embedded derivative exceeding the proceeds that the Company received from the arrangement. Therefore, the Company was required to record a loss on the derivative financial instrument. In addition, the fair value will change in future periods, based upon changes in the Company’s common stock price and changes in other assumptions and market indicators used in the valuation techniques. These future changes will be currently recognized in other expense or other income on the Company’s statement of operations. Accordingly, the Company recognized the change in fair value of derivative in the amount of $27,756 and $13,119 during the nine months ended September 30, 2012 and the year of 2011.The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock

XML

OTHER DEBT (Details Textual) (USD $)	3 Months Ended			9 Months Ended					9 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended		3 Months Ended	9 Months Ended		9 Months Ended		9 Months Ended		1 Months Ended			1 Months Ended		9 Months Ended		12 Months Ended			12 Months Ended				9 Months Ended			9 Months Ended			9 Months Ended	12 Months Ended	3 Months Ended
	Sep. 30, 2012		Sep. 30, 2011	Sep. 30, 2012		Sep. 30, 2011	Dec. 31, 2011		Sep. 30, 2012 Restricted Stock [Member]	Mar. 31, 2012 Liquid Package Resources Inc [Member]	Sep. 30, 2012 Liquid Package Resources Inc [Member]	Dec. 31, 2011 Liquid Package Resources Inc [Member]	Aug. 02, 2011 Liquid Package Resources Inc [Member]	Mar. 31, 2012 Michael Mcdonald Trust [Member]	Sep. 30, 2012 Michael Mcdonald Trust [Member]	Mar. 22, 2012 Michael Mcdonald Trust [Member]	Sep. 30, 2012 Southridge Partners IILLP [Member]	Mar. 26, 2012 Southridge Partners IILLP [Member]	Sep. 30, 2012 Southridge Partners IILLP [Member] October 26, 2012 [Member]	Sep. 30, 2012 Southridge Partners IILLP [Member] October 26, 2012 [Member] Restricted Stock [Member]	May 31, 2011 Note Payable One [Member]	Sep. 30, 2012 Note Payable One [Member]	Dec. 31, 2011 Note Payable One [Member]	Oct. 31, 2011 Note Payable Two [Member]	Sep. 30, 2011 Note Payable Two [Member]	Sep. 30, 2012 Note Payable Two [Member]	Dec. 31, 2011 Note Payable Two [Member]	Dec. 31, 2011 Convertible Note Payable Dated October 27 2011 [Member]	Sep. 30, 2012 Convertible Note Payable Dated October 27 2011 [Member]	Oct. 27, 2011 Convertible Note Payable Dated October 27 2011 [Member]	Dec. 31, 2011 Convertible Note Payable Dated December 5, 2011 [Member]	Sep. 30, 2012 Convertible Note Payable Dated December 5, 2011 [Member]	Dec. 05, 2011 Convertible Note Payable Dated December 5, 2011 [Member]	Sep. 30, 2012 Convertible Note Payable Dated December 5, 2011 [Member] October 31, 2012 [Member]	Sep. 30, 2012 Convertible Note Payable Dated December 5, 2011 [Member] October 31, 2012 [Member] Restricted Stock [Member]	Sep. 30, 2012 Convertible Note Payable Dated February 3, 2012 [Member]	Feb. 03, 2012 Convertible Note Payable Dated February 3, 2012 [Member]	Sep. 30, 2012 Convertible Note Payable Dated February 3, 2012 [Member] TCN International [Member]	Sep. 30, 2012 Convertible Note Payable Dated March 16, 2012 [Member]	Mar. 16, 2012 Convertible Note Payable Dated March 16, 2012 [Member]	Sep. 30, 2012 Convertible Notes Payable [Member]	Dec. 31, 2011 Convertible Notes Payable [Member]	Sep. 30, 2012 Director [Member]	Sep. 30, 2010 Director [Member]	Dec. 31, 2011 Director [Member]
Notes Payable, Related Parties, Current	$ 190,000	[1]		$ 190,000	[1]		$ 200,000	[1]																																				$ 200,000
Repayments of notes payable				35,000		0																																					10,000
Debt Instrument, Interest Rate Terms																					interest calculated at 10% for the first month plus 12% after 30 days from funding.																							interest calculated at 10% for the first month plus 12% after 30 days from funding
Interest Payable, Current																						14,417	8,899			6,666	6,666																78,259		54,423
Notes Payable, Current	879,000	[2]		879,000	[2]		805,000	[2]			250,000					75,000		4,000			50,000			250,000		250,000	500,000
Debt Instrument, Maturity Date																					Dec. 31, 2011					Oct. 01, 2012		Jul. 31, 2012			Sep. 05, 2012					Feb. 13, 2013			Nov. 16, 2012
Debt Instrument, Convertible, Terms of Conversion Feature																										On October 19, 2012 the parties amended the notes to include a conversion feature that would allow them to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company''s stock traded over the previous 5 days.		The convertible note payable is convertible, at the holder''s option, into the Company''s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower.			The convertible note payable is convertible, at the holder''s option, into the Company''s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower.					Redwood Management, LLC has the right to convert the note, until is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company''s common stock, during the 15 trading days prior to conversion (the "Set Price").			Southridge Partners II, LLC is entitled after six months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the "conversion price"). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date.
Stock Issued During Period, Shares, Restricted Stock Award, Gross																										4,000,000
Debt Instrument, Frequency of Periodic Payment																										monthly
Debt Instrument, Interest Rate During Period															3.00%									12.00%	20.00%
Settlement Agreement Initiation Date												Aug. 02, 2011
Settlement Agreement Consideration1												175,000	350,000
Settlement Agreement Consideration Monthly Installment Payment												50,000
Settlement Agreement Amendment Date											Jan. 26, 2012
Settlement Agreement Penalty Amount												25,000
Settlement Agreement Damages Paid Value										25,000
Stock Issued During Period, Shares, New Issues											5,714,326
Settlement Agreement Settlement In Cash Total											450,000
Settlement Agreement Settlement In Cash Initial Amount											350,000
Settlement Agreement Settlement In Cash Penalty Amount											100,000
Settlement Agreement Penalty Expenses										100,000
Proceeds from notes payable				79,000		575,000								25,000	50,000
Debt Instrument Maturity Period															6 months		45 days
Debt Instrument, Periodic Payment, Interest																	500
Debt Conversion, Converted Instrument, Shares Issued									7,000,000										497,238	5,919,495															20,000,000			7,500,000
Debt Instrument, Face Amount	368,648			368,648			90,500																							53,000			37,500	100,000			40,000			75,000
Debt Instrument, Interest Rate, Stated Percentage																														8.00%			8.00%				12.00%			8.00%
Convertible Notes at Fair Value	395,020	[3]		395,020	[3]		206,863	[3]																				120,444	105,361		86,819	74,548				109,386			105,725
Common Stock Price Per Share (in dollars per share)									$ 0.0221																										$ 0.005			$ 0.007
Derivative, Loss on Derivative																																									100,914	103,244
Change in fair value of derivatives	(57,986)		7,167	(83,447)		26,667																																			27,756	13,119
Assignment Debt Consideration Amount Total																																						52,500
Extinguishment of Debt, Amount																																						$ 52,500

[1] During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 during the third quarter of 2012. Under the terms of the loan agreement this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At September 30, 2012 and December 31, 2011, we owed this director accrued interest of $78,259 and $54,423, respectively.

[2] At September 30, 2012, the balance consisted of the following loans: · In May 2011, the Company received two loans for a total of $50,000 from non-related parties. These loans were expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. These loans are guaranteed by an officer of the Company. The Company was unable to repay the loans and they continue to accrue interest. At September 30, 2012 and December 31, 2011, the accrued interest payable was $14,417 and $8,899, respectively. · In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans was to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 5 days. The Company will also issue a total of 4,000,000 restricted shares to the note holders per the amendment. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At September 30, 2012 and December 31, 2011, the accrued interest was $6,666 at each period end. · On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. ("LPR"), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement whereunder we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment).The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company's free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during the quarter ended March 31, 2012. On June 11, 2012, LPR sold the note to Southridge Partners, LLP ("Southridge"). Once the debt is satisfied, LPR will return all of the Company's collateral shares currently held by LPR's attorney. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt. The balance due LPR at September 30, 2012 is $250,000. · On March 22, 2012 the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000. $25,000 of the funds was received during the first quarter of 2012. The remaining amount of $50,000 was received during the third quarter of 2012. The note is due and payable on the date that is six months from the execution and funding of the note. Interest is based on a rate of three (3%) percent per month to be accrued from the later of the date of the note or receipt of funds until all principal has been paid. In August 2012, McDonald Trust sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt. · On March 26, 2012, the Company issued a promissory note to Southridge Partners II, LP in the amount of $4,000. The term of the note was 45 days and bears a flat interest of $500. On October 26, 2012 Southridge converted the note into 497,238 shares of restricted common stock in full satisfaction of the note.

[3] Convertible Notes - At Fair Value: Convertible Note Payable Dated October 27, 2011 at Fair Value - On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $105,361 and $120,044. Convertible Note Payable Dated December 5, 2011 at Fair Value - On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $74,548 and $86,819.During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares at $0.005 per share. Convertible Note Payable Dated February 3, 2012 at Fair Value - On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the Set Price"). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company at the recent low bid of $0.007 per share, providing 7,500,000 (seven million, five hundred thousand) shares of Nutra Pharma common stock to relinquish the total debt of $52,500.At September 30, 2012, this convertible note payable, at fair value, was recorded at $109,386. Convertible Note Payable Dated March 16, 2012 at Fair Value - On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the "conversion price"). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.At September 30, 2012, this convertible note payable, at fair value, was recorded at $105,725.The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $100,914 and $103,244, respectively at September 30, 2012 and December 31, 2011 related to the recognition of (i) the hybrid note and (ii) the derivative instrument arising from the fair value measurement due to the fair value of the hybrid note and embedded derivative exceeding the proceeds that the Company received from the arrangement. Therefore, the Company was required to record a loss on the derivative financial instrument. In addition, the fair value will change in future periods, based upon changes in the Company’s common stock price and changes in other assumptions and market indicators used in the valuation techniques. These future changes will be currently recognized in other expense or other income on the Company’s statement of operations. Accordingly, the Company recognized the change in fair value of derivative in the amount of $27,756 and $13,119 during the nine months ended September 30, 2012 and the year of 2011.The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock

XML

SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Short-term Debt [Text Block]

3. SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE

Redwood Management Agreement – Bank of America and Post Graduate Healthcare Education, LLC

At December 31, 2011 the Company owed Bank of America approximately $80,000 representing the balance of a credit line originated on September 28, 2006. On January 4, 2012 Bank of America assigned and sold this debt to Great Plains Capital Corporation (“Great Plains”). On February 3, 2012 Great Plains assigned the debt to Redwood Management, LLC (“Redwood”) for consideration of $34,108.

At December 31, 2011 the Company owed Post Graduate Healthcare Education, LLC (“Post Graduate”) $109,500 representing the balance of a total debt of $149,500. On February 3, 2012 Post Graduate assigned the debt to Redwood Management, LLC for consideration of $54,750.

The total amount of the Company’s debt assigned to Redwood was $188,608. On February 3, 2012 under a Securities Settlement Agreement, the Company issued a Convertible Debenture to Redwood for $188,608 payable within six months with interest at 6% annum. The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion. Following the agreement Redwood accepted 18,737,894 shares of our restricted stock as satisfaction for the note.

Coventry Enterprises, LLC – Alera Technologies, Inc.

At December 31, 2011 the Company owed Alera Technologies, Inc. (“Alera”) $65,040 representing the balance of a purchase order for the production of Nyloxin™ products. On March 22, 2012 Alera assigned the rights to the debt to Coventry Enterprises, LLC (“Coventry”) in exchange for a payment to Alera by Coventry of $65,040.

On March 22, 2012 the Company issued a Convertible Redeemable Note in favor of Coventry in the amount of $65,040 bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date. The note was satisfied on April 5, 2012 in exchange for 8,672,090 shares of restricted Common Stock.

The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.

In connection with the issuance of these convertible notes payable, the Company recognized the change in fair value of derivatives in the amount of $21,789 and loss on settlement of accounts payable of $213,090 during the nine months ended September 30, 2012.

XML

STOCKHOLDERS' DEFICIT (Details Textual) (USD $)	3 Months Ended		9 Months Ended				3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	1 Months Ended		9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended		12 Months Ended		9 Months Ended						12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Investor [Member]	Sep. 30, 2012 Restricted Stock [Member]	Sep. 30, 2012 Restricted Stock [Member] Investor [Member]	Sep. 30, 2012 Restricted Stock [Member] October 26, 2012 [Member]	Sep. 30, 2012 Restricted Stock [Member] October 2012 [Member] Investor [Member]	Sep. 30, 2012 Jpu Ventures Inc [Member]	Aug. 31, 2012 Jpu Ventures Inc [Member] Restricted Stock [Member]	Mar. 31, 2012 Jpu Ventures Inc [Member] Restricted Stock [Member]	Sep. 30, 2012 Synergy Financial Llc [Member]	Dec. 31, 2011 Synergy Financial Llc [Member]	Sep. 30, 2012 Synergy Financial Llc [Member] Restricted Stock [Member]	Dec. 31, 2011 Synergy Financial Llc [Member] Restricted Stock [Member]	Sep. 30, 2012 Synergy Financial Llc [Member] Restricted Stock [Member] November 1 2011 [Member]	Sep. 30, 2012 Synergy Financial Llc [Member] Restricted Stock [Member] December 1 2011 [Member]	Mar. 31, 2012 Drc Partners Llc [Member]	Sep. 30, 2012 Drc Partners Llc [Member]	Dec. 31, 2011 Drc Partners Llc [Member]	Jan. 02, 2012 Drc Partners Llc [Member]	Dec. 31, 2011 Drc Partners Llc [Member] Restricted Stock [Member]	Dec. 31, 2011 Liquid Packaging Resources Inc [Member]	Sep. 30, 2012 Redwood Management Llc [Member] Restricted Stock [Member]	Sep. 30, 2012 Coventry Enterprises Llc [Member]	Sep. 30, 2012 Coventry Enterprises Llc [Member] Restricted Stock [Member]	Sep. 30, 2012 Capital Path Securities Llc [Member]	Sep. 30, 2012 Employees and Directors [Member] Restricted Stock [Member]	Sep. 30, 2012 Consultant One [Member]	Dec. 31, 2011 Consultant Two [Member]	Dec. 31, 2011 Consultant Two [Member] Restricted Stock [Member]	Dec. 31, 2011 Consultant Two [Member] Restricted Stock [Member] January 10 2012 [Member]	Dec. 31, 2011 Consultant Two [Member] Restricted Stock [Member] February 10 2012 [Member]	Dec. 31, 2011 Consultant Two [Member] Restricted Stock [Member] March 10 2012 [Member]	Dec. 31, 2011 Consultant Two [Member] Restricted Stock [Member] April 10 2012 [Member]	Dec. 31, 2011 Consultant Three [Member]	Dec. 31, 2011 Consultant Three [Member] Restricted Stock [Member]	Dec. 31, 2011 Consultant Three [Member] Restricted Stock [Member] July 11 2011 [Member]	Dec. 31, 2011 Consultant Three [Member] Restricted Stock [Member] October 11 2011 [Member]	Dec. 31, 2011 Consultant Three [Member] Restricted Stock [Member] January 11 2011 [Member]
Stock Issued During Period, Shares, New Issues							27,000,000																	5,714,286					15,720,000
Common Stock Price Per Share (in dollars per share)					$ 0.01	$ 0.0221	$ 0.01				$ 0.007	$ 0.0186		$ 0.05		$ 0.06							$ 0.06						$ 0.0165	$ 0.02								$ 0.07
Investment Warrants Expiration Date					Dec. 13, 2014				Dec. 31, 2014
Proceeds From Issuance Of Common Stock			$ 270,000	$ 159,500			$ 270,000
Warrants To Purchase Common Stock Share									27,000,000
Warrants To Purchase Common Stock Per Share Value (in dollars per share)					$ 0.1				$ 0.10
Stock Issued During Period, Shares, Issued for Services								10,000,000			6,000,000	6,000,000			500,000	300,000							100,000							3,000,000		1,000,000	250,000	250,000	250,000	250,000	250,000	1,000,000	250,000	250,000	250,000
Investor Relations Services Agreement Initiation Date										Mar. 19, 2012				Jul. 27, 2011							Jul. 25, 2011									Mar. 16, 2012	Dec. 20, 2011						Apr. 11, 2011
Investor Relations Services Agreement Period										six months				three months							month to month basis									six months	six months						one year
Investor Relations Services Agreement Initiation Date One										Aug. 13, 2012
Stock Payable Number Of Tranches																																four						Three
Monthly Payment Of Cash For Investor Relations Services														5,000							5,000
Monthly Payment Of Cash For Investor Relations Services One														5,000
Stock Issued During Period Shares Issued For Services One																300,000							100,000
Other Expenses														15,000
Investor Relations Services Agreement Extension Period													three months	three months
Stock To Be Issued During Period Shares For Services															1,000,000
Amount Of Cash Stock Issued															10,000		5,000	5,000
Debt Conversion, Converted Instrument, Shares Issued						7,000,000														400,000					18,737,894		8,672,090
Long-term Debt, Gross																					16,239
Stock To Be Issued During Period In Settlement Of Debt						7,000,000																	400,000
Amount Of Debt Assigned To Third Party Total																						175,000
Gains (Losses) On Extinguishment Of Debt	0	0	(213,090)	0															36,539							213,090
Debt Conversion, Converted Instrument, Amount																									320,531		168,889
Equity Line Of Credit																												10,000,000
Placement Fee Percentage																												5.00%
Additional Equity Line Of Credit																												$ 3,000,000

XML

Consolidated Condensed Balance Sheets (USD $)	Sep. 30, 2012	Dec. 31, 2011
ASSETS
Cash	$ 9,115	$ 0
Subscription receivable	0	8,000
Inventory-net	117,800	117,800
Prepaid expenses and other current assets	4,000	32,375
Total current assets	130,915	158,175
Property and equipment, net	43,260	54,509
Other assets	16,621	16,621
TOTAL ASSETS	190,796	229,305
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	850,772	1,098,452
Accrued expenses	969,677	951,073
Due to officers	841,223	850,529
Other debt	1,464,020	1,211,863
Total current liabilities	4,125,692	4,111,917
Derivative Warrant Liability	17,333	28,833
Stockholders' deficit:
Common stock, $0.001 par value, 2,000,000,000 shares authorized; 388,217,943 shares issued and 382,503,657 shares outstanding at September 30, 2012 321,027,959 shares issued and 315,313,673 shares outstanding at December 31, 2011	388,218	321,027
Common stock issuable	270,000	139,834
Additional paid-in capital	30,846,522	29,659,199
Accumulated deficit	(35,456,969)	(34,031,505)
Total stockholders' deficit	(3,952,229)	(3,911,445)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 190,796	$ 229,305

XML

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Nutra Pharma Corp. ("Nutra Pharma"), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.

Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin, an over-the-counter pain reliever that is a stronger version of Cobroxin and is designed to treat severe chronic pain.

Basis of Presentation and Consolidation

The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K.

The accompanying consolidated financial statements include the accounts of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.

Liquidity and Going Concern

Our consolidated financial statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $35,456,969at September 30, 2012. In addition, we had respective working capital and stockholders’ deficits at September 30, 2012 of $3,994,777 and $3,952,229.

Our ability to continue as a going concern is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate, and in our particular situation because our securities have been removed from quotation on the OTC Bulletin Board.

As of September 30, 2012, we had no material cash balances. We currently do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding, however proceeds from such funding have not been sufficient to execute our business plan. Our plans are to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.

The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our possible inability to continue as a going concern.

Use of Estimates

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.

Revenue Recognition

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns. In 2011, the Company recorded a return allowance of $503,958 representing products sold to Nutritional Alliance during 2011 and returned in March of 2012. The products were subsequently written off as worthless.

Cash and Cash Equivalents

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Accounts Receivable and Allowance for Doubtful Accounts

The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.

Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.

Inventories

Inventories, which are stated at the lower of average cost or market, consist mostly of raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold. We performed evaluations of our inventory during the nine months ended September 30, 2012 and believe no allowance is needed with respect to the raw venom.

Financial Instruments and Concentration of Credit Risk

Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transaction in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.

Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Property and Equipment and Long-Lived Assets

Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.

We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At September 30, 2012, we believe the carrying values of our long-lived assets are recoverable.

Advertising

All advertising costs are expensed as incurred. Advertising costs were $2,500 and $31,487 for the three months ended September 30, 2012 and 2011, respectively, and $20,504 and $90,303 for the nine months ended September 30, 2012 and 2011, respectively.

Research and Development

Research and development is charged to operations as incurred. We incurred research and development expenses of $0 and $17,255 for the three months ended September 30, 2012 and 2011, respectively, and $3,046 and $87,239 for the nine months ended September 30, 2012 and 2011, respectively.

Net Loss Per Share

Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share.

Reclassifications

Certain amounts in the 2011 consolidated financial statements have been reclassified to conform to the current period presentation.

XML

STOCK OPTIONS AND WARRANTS (Details 2) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Warrants, Weighted Average Number Outstanding (in shares)	47,921,667	47,921,667	47,921,667	44,315,000
Warrants, Weighted Average Contractual Life	4 months 28 days
Warrants, Weighted Average Exercise Price	$ 0.10	$ 0.10	$ 0.10	$ 0.10
Minimum [Member]
Warrants, Exercise Price	$ 0.10
Maximum [Member]
Warrants, Exercise Price	$ 0.15

XML

FAIR VALUE MEASUREMENTS (Details) (USD $)	Sep. 30, 2012		Dec. 31, 2011		Sep. 30, 2011	Dec. 31, 2010
Liabilities:
Warrant liability	$ 17,333		$ 28,833			$ 109,500
Convertible Notes at Fair Value	395,020	[1]	206,863	[1]
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liability	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liability	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liability	17,333
Convertible Notes at Fair Value	$ 395,020		$ 206,863		$ 82,833	$ 109,500

[1] Convertible Notes - At Fair Value: Convertible Note Payable Dated October 27, 2011 at Fair Value - On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $105,361 and $120,044. Convertible Note Payable Dated December 5, 2011 at Fair Value - On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the "Default Put").At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $74,548 and $86,819.During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares at $0.005 per share. Convertible Note Payable Dated February 3, 2012 at Fair Value - On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the Set Price"). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company at the recent low bid of $0.007 per share, providing 7,500,000 (seven million, five hundred thousand) shares of Nutra Pharma common stock to relinquish the total debt of $52,500.At September 30, 2012, this convertible note payable, at fair value, was recorded at $109,386. Convertible Note Payable Dated March 16, 2012 at Fair Value - On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the "conversion price"). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.At September 30, 2012, this convertible note payable, at fair value, was recorded at $105,725.The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $100,914 and $103,244, respectively at September 30, 2012 and December 31, 2011 related to the recognition of (i) the hybrid note and (ii) the derivative instrument arising from the fair value measurement due to the fair value of the hybrid note and embedded derivative exceeding the proceeds that the Company received from the arrangement. Therefore, the Company was required to record a loss on the derivative financial instrument. In addition, the fair value will change in future periods, based upon changes in the Company’s common stock price and changes in other assumptions and market indicators used in the valuation techniques. These future changes will be currently recognized in other expense or other income on the Company’s statement of operations. Accordingly, the Company recognized the change in fair value of derivative in the amount of $27,756 and $13,119 during the nine months ended September 30, 2012 and the year of 2011.The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock

XML

STOCK OPTIONS AND WARRANTS (Details Textual) (USD $)		12 Months Ended		12 Months Ended
	Sep. 30, 2012	Dec. 31, 2003 Plan Member 2003 [Member]	Sep. 30, 2012 Plan Member 2003 [Member]	Dec. 31, 2011 Plan Member 2007 [Member]	Dec. 31, 2007 Plan Member 2007 [Member]	Sep. 30, 2012 Plan Member 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		2,500,000			25,000,000
Common Stock, Capital Shares Reserved for Future Issuance			5,000			3,035,715
Stock Issued During Period, Shares, New Issues				5,714,236
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value (in dollars)	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value (in dollars)	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0.009

XML

FAIR VALUE MEASUREMENTS (Details 2) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Debenture Face Amount	$ 368,648	$ 90,500
Debenture Face Amount, Total	$ 459,148
Debenture Interest Rate		8.00%
Debenture Interest Rate, Minimum	6.00%
Debenture Interest Rate, Maximun	12.00%
Debenture Default Interest Rate		30.00%
Debenture Conversion Price, Percentage of VWAP for Look-back Period		58.00%
Debenture Look-back Period		10 days
Minimum [Member]
Debenture Conversion Price, Anti-Dilution Adjusted Price	$ 0.0070	$ 0.0055
Debenture Conversion Price, Percentage of VWAP for Look-back Period	50.00%
Debenture Look-back Period	5 days
Maximum [Member]
Debenture Conversion Price, Anti-Dilution Adjusted Price	$ 0.0137	$ 0.029
Debenture Conversion Price, Percentage of VWAP for Look-back Period	75.00%
Debenture Look-back Period	20 days

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

2. FAIR VALUE MEASUREMENTS

Certain assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2011 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.

The statement requires fair value measurement be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The following table summarizes our financial instruments measured at fair value as of September 30, 2012:

	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Liabilities:
Warrant liability	$	17,333	$	–	$	–	$	17,333
Convertible Notes at Fair Value	$	395,020					$	395,020

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the nine months ended September 30, 2012 and the year ended December, 31, 2011:

	Nine months Ended			Year Ended
	September 30,			December 31,
Description	2012			2011
Beginning balance	$	28,833		$	109,500
Purchases, issuances, and settlements		-			-
Total gain included in earnings (1)		(11,500	)		(80,667	)
Ending balance	$	17,333		$	28,833

(1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations.

The Company values its warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 1.13% to .36% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 127% to 130% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted.

The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of September 30, 2012

									Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period
Debenture	Face					Default Interest			Anti- Dilution Adjusted				Look-back
Issuance Year	Amount		Interest Rate			Rate			Price	%			Period
2011	$	90,500		8.00	%		30	%	$0.0055-$0.029		58	%	10 days
2012		368,648		6%-12%			n/a		$0.0070-$0.0137		50%-75%		5 to 20 Days
Total	$	459,148

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the nine months ended September 30, 2012 and 2011 for the Convertible Notes

	Nine months ended September 30,
	2012			2011
Description
Beginning balance	$	206,863		$	109,500
Purchases, issuances, and settlements		368,648			-
Day one loss on value of hybrid instrument		314,896			-
(Gain) loss from change in fair value		(5,967	)		(26,667	)
Conversion to common stock		(489,420	)		-
Ending balance	$	395,020		$	82,833

XML

Consolidated Condensed Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2012	Dec. 31, 2011
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	388,217,943	321,027,959
Common stock, shares outstanding	382,503,657	315,313,673

XML

DUE TO OFFICERS (Tables)

9 Months Ended

Sep. 30, 2012

Due To Officers [Abstract]

Due To Officers [Table Text Block]

At September 30, 2012 and December 31, 2011, the balance due to officers consisted of the following:

	September 30, 2012		December 31, 2011
An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at September 30, 2012 and December 31, 2011, respectively, includes accrued interest payable of $317,790 and $297,980.	$	725,464	$	738,993
A loan from Paul Reid, the President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero interest rate at September 30, 2012 and December 31, 2011.		115,759		111,536
Ending balances	$	841,223	$	850,529

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2012	Nov. 26, 2012
Entity Registrant Name	NUTRA PHARMA CORP
Entity Central Index Key	0001119643
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	nphc
Entity Common Stock, Shares Outstanding		522,134,676
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2012

XML

OTHER DEBT (Tables)

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Schedule of Short-term Debt [Table Text Block]

Other debt (all short-term) consists of the following at September 30, 2012 and December 31, 2011:

	September 30, 2012		December 31, 2011
Note payable – Related Party   (1)	$	190,000	$	200,000
Notes payable – Non Related Parties  (2)		879,000		805,000
Convertible notes payable, at fair value (3)		395,020		206,863
Ending balances	$	1,464,020	$	1,211,863

(1) During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 during the third quarter of 2012. Under the terms of the loan agreement this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At September 30, 2012 and December 31, 2011, we owed this director accrued interest of $78,259 and $54,423, respectively.

(2) At September 30, 2012, the balance consisted of the following loans:

· In May 2011, the Company received two loans for a total of $50,000 from non-related parties. These loans were expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. These loans are guaranteed by an officer of the Company. The Company was unable to repay the loans and they continue to accrue interest. At September 30, 2012 and December 31, 2011, the accrued interest payable was $14,417 and $8,899, respectively.

· In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans was to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 5 days. The Company will also issue a total of 4,000,000 restricted shares to the note holders per the amendment. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At September 30, 2012 and December 31, 2011, the accrued interest was $6,666 at each period end.

· On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement whereunder we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment).

The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during the quarter ended March 31, 2012. On June 11, 2012, LPR sold the note to Southridge Partners, LLP (“Southridge”). Once the debt is satisfied, LPR will return all of the Company's collateral shares currently held by LPR's attorney. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt. The balance due LPR at September 30, 2012 is $250,000.

· On March 22, 2012 the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000. $25,000 of the funds was received during the first quarter of 2012. The remaining amount of $50,000 was received during the third quarter of 2012. The note is due and payable on the date that is six months from the execution and funding of the note. Interest is based on a rate of three (3%) percent per month to be accrued from the later of the date of the note or receipt of funds until all principal has been paid. In August 2012, McDonald Trust sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt.

· On March 26, 2012, the Company issued a promissory note to Southridge Partners II, LP in the amount of $4,000. The term of the note was 45 days and bears a flat interest of $500. On October 26, 2012 Southridge converted the note into 497,238 shares of restricted common stock in full satisfaction of the note.

(3) Convertible Notes – At Fair Value

Convertible Note Payable Dated October 27, 2011 at Fair Value

On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”).

At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $105,361 and $120,044.

Convertible Note Payable Dated December 5, 2011 at Fair Value

On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”).

At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $74,548 and $86,819.

During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares at $0.005 per share.

Convertible Note Payable Dated February 3, 2012 at Fair Value

On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company at the recent low bid of $0.007 per share, providing 7,500,000 (seven million, five hundred thousand) shares of Nutra Pharma common stock to relinquish the total debt of $52,500.

At September 30, 2012, this convertible note payable, at fair value, was recorded at $109,386.

Convertible Note Payable Dated March 16, 2012 at Fair Value

On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.

At September 30, 2012, this convertible note payable, at fair value, was recorded at $105,725.

The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.

In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $100,914 and $103,244, respectively at September 30, 2012 and December 31, 2011 related to the recognition of (i) the hybrid note and (ii) the derivative instrument arising from the fair value measurement due to the fair value of the hybrid note and embedded derivative exceeding the proceeds that the Company received from the arrangement. Therefore, the Company was required to record a loss on the derivative financial instrument. In addition, the fair value will change in future periods, based upon changes in the Company’s common stock price and changes in other assumptions and market indicators used in the valuation techniques. These future changes will be currently recognized in other expense or other income on the Company’s statement of operations. Accordingly, the Company recognized the change in fair value of derivative in the amount of $27,756 and $13,119 during the nine months ended September 30, 2012 and the year of 2011.

The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.

Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders.

On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock

XML

Consolidated Condensed Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net sales	$ 13,221	$ 251,830	$ 44,456	$ 651,279
Cost of sales	4,260	88,476	10,626	181,546
Gross profit	8,961	163,354	33,830	469,733
Other costs and expenses:
Selling, general and administrative	213,987	791,776	1,044,748	2,235,457
Research and development	0	17,255	3,046	87,239
Interest expense	39,772	23,248	114,963	71,738
Total costs and expenses	253,759	832,279	1,162,757	2,394,434
Net Loss from Operations	(244,798)	(668,925)	(1,128,927)	(1,924,701)
Other Income (Expenses)
Change in fair value of derivatives	(57,986)	7,167	(83,447)	26,667
Gain (loss) on settlement of debt and accounts payable	0	0	(213,090)	0
Total other expense, net	(57,986)	7,167	(296,537)	26,667
Net Loss	$ (302,784)	$ (661,758)	$ (1,425,464)	$ (1,898,034)
Per share information - basic and diluted:
Loss per common share (in dollars per share)	$ 0.00	$ 0.00	$ 0.00	$ (0.01)
Weighted average common shares outstanding (in shares)	381,086,075	300,561,055	371,289,580	292,830,924

XML

STOCK OPTIONS AND WARRANTS

9 Months Ended

Sep. 30, 2012

Equity [Abstract]

Shareholders' Equity and Share-based Payments [Text Block]

7. STOCK OPTIONS AND WARRANTS

Equity Compensation Plans

On December 3, 2003, the Board of Directors approved the Employee/Consultant Stock Compensation Plan (the "2003 Plan"). The purpose of the 2003 Plan is to further our growth by allowing us to compensate employees and consultants who have provided bona fide services to us, through the award of our common stock. The maximum number of shares of common stock that may be issued under the 2003 Plan is 2,500,000. At September 30, 2012, a total of 5,000 shares of common stock were available to be issued under the 2003 Plan.

On June 6, 2007 the Board of Directors approved the 2007 Employee/Consultant Stock Compensation Plan (the "2007 Plan"). The purpose of the 2007 Plan is to further our growth by allowing us to compensate employees and consultants who have provided bona fide services to us, through the award of our common stock. The maximum number of shares of common stock that may be issued under the 2007 Plan is 25,000,000. On July 27, 2011 the Company issued 5,714,236 shares to be placed in escrow under a settlement agreement with Liquid Packaging Resources, Inc. dated August 2, 2011. At September 30, 2012, a total of 3,035,715 shares of common stock were available to be issued under the 2007 Employee/Consultant Stock Compensation Plan.

The Board of Directors is responsible for the administration of the 2003 and 2007 Plans and has full authority to grant awards under the Plan. Awards may take the form of stock grants, options or warrants to purchase common stock. The Board of Directors has the authority to determine: (a) the employees and consultants that will receive awards under the Plan, (b) the number of shares, options or warrants to be granted to each employee or consultant, (c) the exercise price, term and vesting periods, if any, in connection with an option grant, and (d) the purchase price and vesting period, if any, in connection with the granting of a warrant to purchase shares of our common stock.

No options were issued under the plans during 2011 and nine months ended September 30, 2012.

We account for option and stock awards under our option plans in accordance with ASC Topic 718, Compensation – Stock Compensation, which requires the measurement and recognition of compensation expense in our statement of operations for all share-based option and stock awards, based on estimated grant-date fair values.

ASC Topic 718 requires us to estimate the fair value of stock-based option awards on the date of grant using an option-pricing model. The grant-date fair value of the award is recognized as expense over the requisite service period using the straight-line method. In accordance with ASC Topic 718, the estimated stock-based compensation expense to be recognized is reduced by an estimate of the annualized rate of stock option forfeitures.

Common Stock Options

A summary of stock options for the three months ended September 30, 2012 and December 31, 2011 is as follows:

			Weighted average exercise price
Balance December 31, 2010	1,000,000		$	0.20
Exercised	-		$	-
Issued	-		$	-
Forfeited	(1,000,000	)	$	0.20
Balance December 31, 2011	-		$	-
Exercised	-		$	-
Issued	-		$	-
Forfeited	-		$	-
Balance September 30, 2012	-		$	-

Common Stock Warrants

From time to time, we issue warrants to purchase its common stock. These warrants have been issued for cash in conjunction with the private placement of shares of our common stock.

A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the three months ended September 30, 2012 and year ended December 31, 2011:

	Number of shares		Weighted average exercise price
Balance December 31, 2010		44,315,000	$	0.10
Exercised		-		-
Issued		3,606,667	$	0.12
Forfeited		-		-
Balance December 31, 2011		47,921,667	$	0.10
Exercised		-		-
Issued		-		0.10
Forfeited		-		-
Balance September 30, 2012		47,921,667	$	0.10

The following table summarizes information about fixed-price warrants outstanding as of September 30, 2012:

Exercise Price		Weighted Average Number Outstanding		Weighted Average Contractual Life		Weighted Average Exercise Price
$	0.10-0.15		47,921,667		0.41 years	$	0.10

As of September 30, 2012, the aggregate intrinsic value of all stock options and warrants outstanding and expected to vest was $0 and the aggregate intrinsic value of currently exercisable stock options was $0. The intrinsic value of each option share is the difference between the fair market value of our common stock and the exercise price of such option share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.009 closing stock price of our common stock on June 29, 2012, the last trading day of the second quarter of 2012. There were no in-the-money options or warrants at September 30, 2012.

There was no intrinsic value of options and warrants exercised during the nine months ended September 30, 2012 and 2011. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options.

XML

STOCKHOLDERS' DEFICIT

9 Months Ended

Sep. 30, 2012

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

6. STOCKHOLDERS' DEFICIT

Private Placements of Common Stock

In the third quarter 2012, the Company sold an aggregate of 27,000,000 shares of restricted common stock to one investor at a price of $0.01 per share and received $270,000. As a result of administrative delays the shares were not issued until October 2012 and are thus recorded as common stock issuable in the accompanying consolidated balance sheet. The Company issued a total of 27,000,000 warrants to purchase common stock at an exercise price of $0.10 per share in October 2012. The warrants expire on December 31, 2014.

Shares Issued to Employees and Directors

On February 3, 2012 the Board of Directors approved a resolution for the issuance of a total of 15,720,000 shares of the Company’s restricted common stock to the Directors and Employees of the Company. The issuance was valued at $0.0165 per share, which was the fair market value of the Company’s common stock on the date of issuance.

Common Stock Issued for Services

During March and August, 2012 the Company issued a total of 6,000,000 shares of the Company’s restricted common stock to JPU Ventures, Inc. under an agreement dated March 19, 2012 and August 13, 2012. The agreement was for investor relations services for a six months term. The shares were valued at $0.0186 and $0.007 per share, which was the fair market value of the Company’s common stock on the date of issuance.

On March 16, 2012 the Company entered into an agreement with Mark Bergman, a consultant. The contract is for an initial six months term. The shares were valued at $0.02 per share, which was the fair market value of the Company’s common stock on the date of issuance. Under the agreement the consultant’s services include the identification of international markets, funding sources for targeted companies and assistance with overall strategic planning and execution. As compensation under this agreement the Company issued 3,000,000 free trading, unrestricted shares on March 16, 2012.

On December 20, 2011 the Company entered into an agreement for investor relations services with a Consultant. The contract was for a six months term and calls as compensation the issuance of 1,000,000 shares of restricted common stock payable in four tranches of 250,000 each as follows: (I) January 10, 2012 (II) February 10, 2012 (III) March 10, 2012 (IV) April 10, 2012. The shares were valued and charged to operations on the dates they were issued. At each issuance date, the fair market value of the shares was adjusted to the actual price on those dates with any adjustments made through our consolidated statements of operations.

On July 27, 2011 the Company signed an agreement for investor relations services with Synergy Financial, LLC. The contract was for a three months term beginning August 1, 2011 and continuing through November 1, 2011 and was renewable by the Company for an additional three months period. The agreement called for a monthly payment for each of the first three months of $5,000 beginning on August 1, 2011 plus the issuance of 300,000 shares of the Company’s restricted common stock on the signing of the agreement. The shares were valued at $0.06 per share, which was the fair market value of the Company’s common stock on the date of issuance. On October 15, 2011 the Company signed a contract extension agreeing to extend the original contract signed on July 27, 2011 for an additional three (3) months under the same terms. Under this extension the Company agreed to pay Synergy Financial, LLC $5,000 monthly on the first of each month starting in November 2011 plus the issuance of 300,000 shares of the company’s restricted common stock upon the signing of the extension agreement. The Company recorded a charge to operations on October 15, 2011 of $15,000, representing the shares to be issued valued at $0.05 per share which was the fair market value of the Company’s common stock on October 15, 2011. The shares were issued on January 12, 2012. On February 8, 2012, the Company further extended the Agreement for an additional 3 months beginning on Feb 9, 2012 and continuing until May 9, 2012. The new extension required the Company to pay Synergy Financial 500,000 shares of NPHC restricted common stock. On March 23, 2012 both parties agreed that Nutra Pharma would issue Synergy Financial 1 million shares of Nutra Pharma restricted common stock in lieu of $10K cash ($5K that was due on November 1, 2011 and $5K that was due on December 1, 2011). Both parties agree that all monthly compensation included in the contact dated on July 27, 2011 and all additional contract extensions have been satisfied in full.

On July 25, 2011 the Company signed an agreement for investor relations services with DRC Partners, LLC. The contract was on a month to month basis and calls for monthly payments of $5,000 in cash and 100,000 shares of restricted stock on the first day of each month of service, beginning August 1, 2011. The Company issued 100,000 shares of restricted common stock on August 22, 2011. The shares were valued at $0.06 per share, which was the fair market value of the Company’s common stock on the date of issuance. The Company did not issue additional shares under this contract. The Company entered into a separate agreement in January of 2012 for the settlement of the outstanding shares owed to DRC Partners, LLC for 400,000 shares.

In April 2011, the Company issued 250,000 shares of restricted common stock to Undiscovered Equities, a consultant for investor and public relations services. The agreement was for one year. Three additional tranches of 250,000 shares of restricted common stock were earned and issued on July 11, 2011, October 11, 2011 and January 11, 2012. At June 30, 2011, all of the shares of restricted stock under the agreement, one million, were valued at $0.07 per share, which was the fair market value of the Company’s common stock on April 11, 2011, the date of the agreement. At each issuance date, the fair market value of the shares is adjusted to the actual price on those dates with any adjustments made through our consolidated statements of operations.

Common Stock Held in Escrow

On July 27, 2011 the Company issued 5,714,286 shares of free trading common stock in certificate form which is held in escrow as security under an agreement reached with Liquid Packaging Resources, Inc. (“LPR”) on August 2, 2011.

Common Stock Issued for Debt

At December 31, 2011 the Company owed DRC Partners, LLC $16,239 plus 400,000 shares of restricted common stock under an agreement for investor relations services entered into July 25, 2011. In satisfaction of this debt our President, Rik Deitsch, assigned $175,000 of the debt owed to him by the Company to the principal of DRC Partners, LLC under an agreement dated January 2, 2012. On January 4, 2012 the Company approved the issuance of 7 million shares of its restricted common stock in satisfaction of the debt. The 7 million shares of restricted common stock were issued on January 6, 2012 and valued at $0.0221 per share, which was the fair market value of the Company’s common stock on the date of issuance. In connection with the settlement agreement for debt, the Company recognized the gain on settlement in the amount of $36,539 during the first quarter of 2012.

Common Stock Issued for Settlement of Accounts Payable & Debt

Following the agreement with Redwood (see Note 3), conversions were made for a total of 18,737,894 shares of the Company’s restricted stock, satisfying the note in full. The shares were valued at a total amount of $320,531, which was the fair value of convertible debts on the date of conversion.

Following the agreement with Coventry Enterprises, LLC (see Note 3), the conversion for a total of 8,672,090 shares of the Company’s restricted common stock satisfying the note in full was made on March 29, 2012, and issued on April 5, 2012. The shares were valued at $168,889, which was the fair value of convertible debts on the date of conversion.

Other Financing

On February 22, 2012 the Company engaged Capital Path Securities, LLC (“CPS”) as its exclusive advisor on a proposed placement by way of an equity line of approximately ten million dollars ($10,000,000) of the Company’s equity or equity linked securities. All upfront fees have been waived by CPS. The Company will pay CPS a cash placement fee equal to 5% of all principal amounts invested from the source originated by CPS. In addition at such time that the Company files an S-1 registration statement for the equity line of credit facilitated by CPS, the Company will include three million shares (3,000,000) registered in the name of Capital Path Securities, LLC. Additionally, for their services as our investment bankers we issued them an additional 10,000,000 restricted shares on October 26, 2012.

XML

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2012		Dec. 31, 2011
Beginning balance	$ 28,833		$ 109,500
Purchases, issuances, and settlements	0		0
Total gain included in earnings	(11,500)	[1]	(80,667)	[1]
Ending balance	$ 17,333		$ 28,833

[1] The gain related to the revaluation of our warrant liability is included in "Change in fair value of derivatives" in the accompanying consolidated statement of operations.

XML

STOCK OPTIONS AND WARRANTS (Tables)

9 Months Ended

Sep. 30, 2012

Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of stock options for the three months ended September 30, 2012 and December 31, 2011 is as follows:

			Weighted average exercise price
Balance December 31, 2010	1,000,000		$	0.20
Exercised	-		$	-
Issued	-		$	-
Forfeited	(1,000,000	)	$	0.20
Balance December 31, 2011	-		$	-
Exercised	-		$	-
Issued	-		$	-
Forfeited	-		$	-
Balance September 30, 2012	-		$	-

Schedule Of Warrants Issued [Table Text Block]

A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the three months ended September 30, 2012 and year ended December 31, 2011:

	Number of shares		Weighted average exercise price
Balance December 31, 2010		44,315,000	$	0.10
Exercised		-		-
Issued		3,606,667	$	0.12
Forfeited		-		-
Balance December 31, 2011		47,921,667	$	0.10
Exercised		-		-
Issued		-		0.10
Forfeited		-		-
Balance September 30, 2012		47,921,667	$	0.10

Schedule Of Warrants Outstanding [Table Text Block]

The following table summarizes information about fixed-price warrants outstanding as of September 30, 2012:

Exercise Price		Weighted Average Number Outstanding		Weighted Average Contractual Life		Weighted Average Exercise Price
$	0.10-0.15		47,921,667		0.41 years	$	0.10

XML

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Consolidation, Policy [Policy Text Block]

Basis of Presentation and Consolidation

The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K.

The accompanying consolidated financial statements include the accounts of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.

Liquidity Disclosure [Policy Text Block]

Liquidity and Going Concern

Our consolidated financial statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $35,456,969at September 30, 2012. In addition, we had respective working capital and stockholders’ deficits at September 30, 2012 of $3,994,777 and $3,952,229.

Our ability to continue as a going concern is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate, and in our particular situation because our securities have been removed from quotation on the OTC Bulletin Board.

As of September 30, 2012, we had no material cash balances. We currently do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding, however proceeds from such funding have not been sufficient to execute our business plan. Our plans are to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.

The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our possible inability to continue as a going concern.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns. In 2011, the Company recorded a return allowance of $503,958 representing products sold to Nutritional Alliance during 2011 and returned in March of 2012. The products were subsequently written off as worthless.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Trade and Other Accounts Receivable, Policy [Policy Text Block]

Accounts Receivable and Allowance for Doubtful Accounts

The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.

Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.

Inventory, Policy [Policy Text Block]

Inventories

Inventories, which are stated at the lower of average cost or market, consist mostly of raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold. We performed evaluations of our inventory during the nine months ended September 30, 2012 and believe no allowance is needed with respect to the raw venom.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Financial Instruments and Concentration of Credit Risk

Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transaction in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.

Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes.

Fair Value Measurement, Policy [Policy Text Block]

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment and Long-Lived Assets

Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.

We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At September 30, 2012, we believe the carrying values of our long-lived assets are recoverable.

Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]

Advertising

All advertising costs are expensed as incurred. Advertising costs were $2,500 and $31,487 for the three months ended September 30, 2012 and 2011, respectively, and $20,504 and $90,303 for the nine months ended September 30, 2012 and 2011, respectively.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development is charged to operations as incurred. We incurred research and development expenses of $0 and $17,255 for the three months ended September 30, 2012 and 2011, respectively, and $3,046 and $87,239 for the nine months ended September 30, 2012 and 2011, respectively.

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Share

Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share.

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain amounts in the 2011 consolidated financial statements have been reclassified to conform to the current period presentation.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Commitments and Contingencies Disclosure [Text Block]

8. COMMITMENTS AND CONTINGENCIES

Litigation

Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc.

On August 18, 2006, ReceptoPharm was named as a defendant in Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06 (New York Supreme Court, Queens County). The original proceeding claimed that ReceptoPharm owed the Plaintiffs, including Patricia Meding, a former ReceptoPharm officer and shareholder and several corporations that she claims to own, the sum of $118,928.15 plus interest and counsel fees on a series promissory notes that were allegedly executed in 2001 and 2002. On August 23, 2007, the Queens County New York Supreme Court issued a decision denying Plaintiffs motion for summary judgment in lieu of a complaint, concluding that there were issues of fact concerning the enforceability of the promissory notes. On May 23, 2008, the Plaintiffs filed an amended complaint in which they reasserted their original claims and asserted new claims seeking damages of no less than $768,506 on their claims that in or about June 2004 ReceptoPharm breached its fiduciary duty to the Plaintiffs as shareholders of ReceptoPharm by wrongfully canceling certain of their purported ReceptoPharm share certificates. In late 2010, Plaintiffs further amended their complaint alleging that ReceptoPharm violated Plaintiffs contractual and statutory rights by cancelling an additional 1,214,800 share certificates and failing to permit the Plaintiffs to exercise dissenting shareholder rights with respect to those share certificates. The damages associated with the Plaintiff’s claims could rise as the result of any increases in the Company’s share price as the ReceptoPharm shares may be convertible into the Company’s common shares. The potential exposure may exceed $10,000,000 if the Plaintiffs are successful with all of their claims.

ReceptoPharm believes the suit is without merit and has filed an answer denying the material allegations of the amended complaint and asserted a series of counterclaims against the Plaintiffs alleging claims for declaratory judgment, fraud, breach of fiduciary duty, and conversion and unjust enrichment as a result of the promissory notes. Plaintiffs have moved for partial summary judgment on their claims regarding the additional 1,214,800 shares, but not on their claims regarding the alleged promissory notes or the additional 1,750,000 shares they alledge they are owed. In August of 2011, the Plaintiff's motion was partially granted. In September 2012, Recepto Pharm's attorneys filed a Motion to be removed as counsel. Their motion is currently being considered. ReceptoPharm is seeking new counsel to oppose the partial summary judgment. We intend to vigorously contest this matter and accordingly no effect has been given to any loss that may result from the resolution of this matter in the accompanying consolidated financial statements.

Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch

On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants in Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch, Superior Court of Fulton County, Georgia, Civil Action No. 2011-CV-199562. Liquid Packaging Resources, Inc. ("LPR") claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $359,826.85 plus interest. LPR also sought punitive damages in the amount of not less than $500,000 and attorney's fees.

That civil action was then removed by Nutra Pharma Corp. and Mr. Deitsch to the United States District Court, Northern District of Georgia, Civil Action No. 11-CV-01663-ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. Nutra Pharma Corp. and Mr. Deitsch moved to dismiss the Complaint on several grounds including statute of frauds, failure to state a claim, and jurisdiction (only for Mr. Deitsch). Nutra Pharma Corp. and Mr. Deitsch believe the suit is without merit.

Subsequent to June 30, 2011, at LPR's request, the parties mediated the dispute before LPR responded to the Motion to Dismiss. At the mediation, the parties worked out an agreement whereby Nutra Pharma would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to Nutra Pharma. The agreed price was $350,000.00 payable over 7 months in equal $50,000.00 amounts. This agreement was reached by Nutra Pharma because it provided tangible value in exchange for the purchase price rather than incurring the expense of litigation which would likely be substantial and not recouped. While Nutra Pharma had counterclaims it could assert, this was a practical resolution. The settlement allowed Nutra Pharma to take possession of the components prior to full payment and, in exchange, provided security to LPR in the form of Nutra Pharma stock valued at $400,000 at the time of issuance. The stock can only be sold in event of a default of the payment schedule. The litigation was dismissed in August of 2011. The Company made the August, September and November payments (totaling $150,000) in a timely fashion. The Company was late for the payment due October 15, 2011 and requested an accommodation from LPR, eventually paying an extra $5,000 towards that payment. At December 31, 2011, the Company had made total payments of $205,000 with an additional $150,000 owed. In order to allow the Company to skip the December payment, LPR agreed to another accommodation whereby the Company would pay both the December and January payment with an additional $10,000 on or before January 16, 2012. The Company was unable to make this payment and on January 26, 2012 signed an amended payment schedule adding an additional $15,000 for a total of $175,000 owed. The Company's CEO, Rik Deitsch, added additional collateral stock in a separate company that he held personally. $25,000 was paid in January, with subsequent payments of $30,000 due monthly on the 15th of March through the 15th of July, 2012. The Company failed to make the March payment and was subsequently called in default of the Agreement. Under the original agreement, if Nutra Pharma is in default of the agreement, LPR has the right to sell shares of the company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 representing the new total cash amount due to LPR by the Company.

On June 11, 2012, LPR sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. We expect to complete those payments by the end of 2012 to satisfy the obligation in its entirety. Once satisfied, LPR will return all of the Company's collateral shares currently held by LPR's attorney. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt.

Laurence N. Raymond v. Receptopharm, Inc. et al.

On December 30, 2011 Laurence N. Raymond ("Raymond") brought the case against Receptopharm, Inc. ("Receptopharm") and Nutra Pharma to recover approximately $300,000 that was allegedly either loaned to Receptopharm or owing to Raymond pursuant to an oral employment agreement. The Complaint alleges that Nutra Pharma is jointly liable for Raymond's damages because Receptopharm was allegedly merged into Nutra Pharma. The parties have engaged in settlement discussions. The outcome of this matter is uncertain, no range of potential loss can be estimated and accordingly no effect has been given to any loss above what has already been accrued that may result from the resolution of this matter in the accompanying consolidated financial statements.

Paul F. Reid v, Harold H. Rumph et al.

On December 28, 2011 Paul F. Reid ("Reid") brought the case against Harold H. Rumph ("Rumph"), Receptopharm, and Nutra Pharma to recover approximately $330,000 that was allegedly either loaned to Receptopharm or owing to Reid pursuant to an oral employment agreement, The Complaint alleges that Nutra Pharma is jointly liable for Reid's damages because Receptopharm was allegedly merged into Nutra Pharma. Nutra Pharma has answered the Complaint and specifically denied the validity of several promissory notes forming the basis of Reid's damages. According to Nutra Pharma, Reid may have a claim for approximately $140,000 (which is included in accruals for disputed services), but any amounts above that are not supported by the record. The parties have engaged in limited discovery to date, including the June 2012 deposition of Rumph. The Company will vigorously defend against this action and, in so doing, will attempt to settle this case favorably and accordingly no effect has been given to any loss above what has already been accrued that may result from the resolution of this matter in the accompanying consolidated financial statements

Dustin Travers v, XenaCare Holdings, Inc., et al.

On March 7, 2012 XenaCare Holdings and Nutra Pharma were named as Defendants in the proposed Class Action filed in the Superior Court of California. Travers alleges that the marketing of the Homeopathic drug, Cobroxin included false and misleading statements regarding the product's efficacy for the relief of chronic pain. Most of the suit is a diatribe against the entire concept of homeopathy and states, incorrectly, that cobra venom has never been proven scientifically as a pain reliever. On August 10, 2012 the parties reached a settlement whereby the suit would be dismissed against Nutra Pharma in return for $16,500 payable in 6 monthly payments of $2,750 beginning on August 20, 2012 with the last payment due on January 20, 2013. As part of the settlement, the Company will also make certain label changes to the Cobroxin packaging that better explain the product as a Homeopathic drug. Nutra Pharma was dismissed as a Defendant with prejudice on August 14, 2012.

Involuntary Petition of Bankruptcy

On August 31, 2012 a Petition for Involuntary Bankruptcy was filed against us by former ReceptoPharm employees and a former consultant to ReceptoPharm in the United States Bankruptcy Court, Southern District of Florida. The Petitioners are claiming a total of $990,927.75 due them in the form of accrued wages and a Note. On October 12, 2012 the Plaintiffs filed an amended Petition, in effect lowering their claims to $816,662.39. We believe that the petition is frivolous and that their claims lack merit. The Company will vigorously defend against this action and accordingly no effect has been given to any loss above what has already been accrued that may result from the resolution of this matter in the accompanying consolidated financial statements.

Shelter Developers of America vs. ReceptoPharm, Inc.

On June 7, 2012 Shelter Developers of America enforced a Writ of Possession against ReceptoPharm as a result of ReceptoPharm’s failure to pay its obligations under the lease agreement dated May 10, 2010 between ReceptoPharm and Shelter Developers of America. On July 9, 2012 the Company issued a bank draft in the amount of $38,934.90 in satisfaction of all amounts owed under the lease, including legal fees. On July 9, 2012 ReceptoPharm entered into a new lease agreement with Shelter Developers of America for a five year period beginning on August 1, 2012.

OTC:BB Delinquency Notification

On May 7, 2012 the Company’s securities were removed from quotation on the OTC Bulletin Board (“OTCBB”) as a result of the failure to file its annual report, Form 10-K, by the due date of May 17, 2012, which includes the 30-day grace period allowed. The Company was also delinquent in the filing of its first, second and third quarter 10-Q reports for 2012. As of the date hereof the Form 10-K and Form 10-Q’s for the first and second quarters of 2012 have been filed.

Pursuant to National Association of Securities Dealers (“NASD”) Rule 6530, OTCBB issuers that are cited for filing delinquency three times in a 24-month period and those removed for failure to file two times in a 24-month period will be ineligible for quotation by an NASD member and shall not be eligible for quotation until the issuer has timely filed in a complete form all required annual and quarterly reports due in a one-year period.

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]

9. SUBSEQUENT EVENTS

Other Subsequent Issuances

Description	Month of Issuance		Number of Shares
Shares issued upon conversion of notes payable		October		33,916,733
To our Directors and employees		October		24,000,000
To vendors as satisfaction for 2012 services and materials		October		18,500,000
To ten investors for cash of $.01 per share (warrants to purchase our common stock for $0.10 per share were also issued – the warrants expire on December 13, 2014)		October		38,400,000
Shares issuable under five separate agreements for marketing services		October		15,100,000
Shares issuable to two loan holders		November		4,000,000

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Abstract]

Schedule Of Financial Instruments [Table Text Block]

The following table summarizes our financial instruments measured at fair value as of September 30, 2012:

	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Liabilities:
Warrant liability	$	17,333	$	–	$	–	$	17,333
Convertible Notes at Fair Value	$	395,020					$	395,020

Schedule Of Changes In Financial Instruments [Table Text Block]

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the nine months ended September 30, 2012 and the year ended December, 31, 2011:

	Nine months Ended			Year Ended
	September 30,			December 31,
Description	2012			2011
Beginning balance	$	28,833		$	109,500
Purchases, issuances, and settlements		-			-
Total gain included in earnings (1)		(11,500	)		(80,667	)
Ending balance	$	17,333		$	28,833

(1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations.

Schedule Of Hybrid Financial Instrument Disclosure [Table Text Block]

The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of September 30, 2012

									Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period
Debenture	Face					Default Interest			Anti- Dilution Adjusted				Look-back
Issuance Year	Amount		Interest Rate			Rate			Price	%			Period
2011	$	90,500		8.00	%		30	%	$0.0055-$0.029		58	%	10 days
2012		368,648		6%-12%			n/a		$0.0070-$0.0137		50%-75%		5 to 20 Days
Total	$	459,148

Schedule Of Changes In Hybrid Financial Instruments [Table Text Block]

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the nine months ended September 30, 2012 and 2011 for the Convertible Notes

	Nine months ended September 30,
	2012			2011
Description
Beginning balance	$	206,863		$	109,500
Purchases, issuances, and settlements		368,648			-
Day one loss on value of hybrid instrument		314,896			-
(Gain) loss from change in fair value		(5,967	)		(26,667	)
Conversion to common stock		(489,420	)		-
Ending balance	$	395,020		$	82,833

XML

STOCK OPTIONS AND WARRANTS (Details 1) (Warrant [Member], USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Warrant [Member]
Number of shares, Begining Balance	47,921,667	44,315,000
Number of shares, Exercised	0	0
Number of shares, Issued	0	3,606,667
Number of shares, Forfeited	0	0
Number of shares, Ending Balance	47,921,667	47,921,667
Weighted average exercise price, Begining Balance (in dollars per share)	$ 0.10	$ 0.10
Weighted average exercise price, Exercised (in dollars per share)	$ 0	$ 0
Weighted average exercise price, Issued (in dollars per share)	$ 0.10	$ 0.12
Weighted average exercise price, Forfeited (in dollars per share)	$ 0	$ 0
Weighted average exercise price, Ending Balance (in dollars per share)	$ 0.10	$ 0.10

XML

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Entity Incorporation, Date Of Incorporation			Feb. 01, 2000
Retained Earnings (Accumulated Deficit)	$ (35,456,969)		$ (35,456,969)		$ (34,031,505)
Working Capital	3,994,777		3,994,777
Stockholders' Equity Attributable To Parent	(3,952,229)		(3,952,229)		(3,911,445)
Sales Returns and Allowances, Goods					503,958
Advertising Expense	2,500	31,487	20,504	90,303
Research and Development Expense	$ 0	$ 17,255	$ 3,046	$ 87,239
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years

XML

FAIR VALUE MEASUREMENTS (Details Textual) (Warrant [Member])	9 Months Ended
	Sep. 30, 2012
Fair Value Assumptions, Expected Dividend Rate	0.00%
Minimum [Member]
Fair Value Assumptions, Risk Free Interest Rate	0.36%
Fair Value Assumptions, Expected Volatility Rate	127.00%
Maximum [Member]
Fair Value Assumptions, Risk Free Interest Rate	1.13%
Fair Value Assumptions, Expected Volatility Rate	130.00%

XML

Consolidated Condensed Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net cash used in operating activities	$ (569,545)	$ (1,912,629)
Cash flows from investing activities:
Acquisition of property and equipment	0	(1,028)
Cash flows from financing activities:
Repayment of stockholder loans	(9,478)	(688,425)
Proceeds from sale of common stock	270,000	159,500
Proceeds from payment of subscription receivable	8,000	0
Loans from stockholders	151,138	613,720
Proceeds from convertible notes	115,000	0
Proceeds from notes payable	79,000	575,000
Repayments of notes payable	(35,000)	0
Proceeds from common stock purchase agreement	0	1,280,000
Net cash provided by financing activities	578,660	1,939,795
Net (decrease) increase in cash	9,115	26,138
Cash - beginning of period	0	0
Cash - end of period	9,115	26,138
Supplemental Cash Flow Information:
Cash paid for interest	61,076	33,868
Cash paid for income taxes	0	0
Non cash Financing and Investing:
Fair value of warrants issued	0	200,000
Note issued in settlement of payable	253,648	0
Shares issued to satisfy debt	680,659	0
Stock issued for deferred compensation	$ 0	$ 544,000

XML

OTHER DEBT

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Other Debt [Text Block]

5. OTHER DEBT

Other debt (all short-term) consists of the following at September 30, 2012 and December 31, 2011:

	September 30, 2012		December 31, 2011
Note payable – Related Party   (1)	$	190,000	$	200,000
Notes payable – Non Related Parties  (2)		879,000		805,000
Convertible notes payable, at fair value (3)		395,020		206,863
Ending balances	$	1,464,020	$	1,211,863

(1) During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 during the third quarter of 2012. Under the terms of the loan agreement this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At September 30, 2012 and December 31, 2011, we owed this director accrued interest of $78,259 and $54,423, respectively.

(2) At September 30, 2012, the balance consisted of the following loans:

· In May 2011, the Company received two loans for a total of $50,000 from non-related parties. These loans were expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. These loans are guaranteed by an officer of the Company. The Company was unable to repay the loans and they continue to accrue interest. At September 30, 2012 and December 31, 2011, the accrued interest payable was $14,417 and $8,899, respectively.

· In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans was to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 5 days. The Company will also issue a total of 4,000,000 restricted shares to the note holders per the amendment. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At September 30, 2012 and December 31, 2011, the accrued interest was $6,666 at each period end.

· On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement whereunder we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment).

The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during the quarter ended March 31, 2012. On June 11, 2012, LPR sold the note to Southridge Partners, LLP (“Southridge”). Once the debt is satisfied, LPR will return all of the Company's collateral shares currently held by LPR's attorney. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt. The balance due LPR at September 30, 2012 is $250,000.

· On March 22, 2012 the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000. $25,000 of the funds was received during the first quarter of 2012. The remaining amount of $50,000 was received during the third quarter of 2012. The note is due and payable on the date that is six months from the execution and funding of the note. Interest is based on a rate of three (3%) percent per month to be accrued from the later of the date of the note or receipt of funds until all principal has been paid. In August 2012, McDonald Trust sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. The Company is currently negotiating with Southridge Partners to arrange a settlement of the debt.

· On March 26, 2012, the Company issued a promissory note to Southridge Partners II, LP in the amount of $4,000. The term of the note was 45 days and bears a flat interest of $500. On October 26, 2012 Southridge converted the note into 497,238 shares of restricted common stock in full satisfaction of the note.

(3) Convertible Notes – At Fair Value

Convertible Note Payable Dated October 27, 2011 at Fair Value

On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”).

At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $105,361 and $120,044.

Convertible Note Payable Dated December 5, 2011 at Fair Value

On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”).

At September 30, 2012 and December 31, 2011, this convertible note payable, at fair value, was recorded at $74,548 and $86,819.

During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares at $0.005 per share.

Convertible Note Payable Dated February 3, 2012 at Fair Value

On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company at the recent low bid of $0.007 per share, providing 7,500,000 (seven million, five hundred thousand) shares of Nutra Pharma common stock to relinquish the total debt of $52,500.

At September 30, 2012, this convertible note payable, at fair value, was recorded at $109,386.

Convertible Note Payable Dated March 16, 2012 at Fair Value

On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.

At September 30, 2012, this convertible note payable, at fair value, was recorded at $105,725.

The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.

In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $100,914 and $103,244, respectively at September 30, 2012 and December 31, 2011 related to the recognition of (i) the hybrid note and (ii) the derivative instrument arising from the fair value measurement due to the fair value of the hybrid note and embedded derivative exceeding the proceeds that the Company received from the arrangement. Therefore, the Company was required to record a loss on the derivative financial instrument. In addition, the fair value will change in future periods, based upon changes in the Company’s common stock price and changes in other assumptions and market indicators used in the valuation techniques. These future changes will be currently recognized in other expense or other income on the Company’s statement of operations. Accordingly, the Company recognized the change in fair value of derivative in the amount of $27,756 and $13,119 during the nine months ended September 30, 2012 and the year of 2011.

The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.

Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders.

On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock

XML

SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE (Details Textual) (USD $)	3 Months Ended		9 Months Ended			12 Months Ended	9 Months Ended		9 Months Ended			9 Months Ended	12 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Restricted Stock [Member]	Dec. 31, 2011 Bank Of America [Member]	Sep. 30, 2012 Redwood Management Llc [Member]	Feb. 03, 2012 Redwood Management Llc [Member]	Sep. 30, 2012 Redwood Management Llc [Member] Restricted Stock [Member]	Dec. 31, 2011 Post Graduate Healthcare Education Llc [Member]	Dec. 31, 2011 Alera Technologies Inc [Member]	Sep. 30, 2012 Coventry Enterprises Llc [Member]	Dec. 31, 2011 Coventry Enterprises Llc [Member]	Mar. 22, 2012 Coventry Enterprises Llc [Member]	Sep. 30, 2012 Coventry Enterprises Llc [Member] Restricted Stock [Member]
Line of Credit Facility, Amount Outstanding						$ 80,000
Line of Credit Facility, Initiation Date						Sep. 28, 2006
Assigned Debt Consideration Amount							34,108
Long-term Debt, Gross										109,500	65,040
Long-term Debt										149,500
Assigned Debt Consideration Amount One							54,750
Assignment Debt Consideration Amount Total							188,608						65,040
Convertible Debt								188,608						65,040
Debt Instrument, Interest Rate, Stated Percentage								6.00%						8.00%
Debt Instrument, Convertible, Terms of Conversion Feature							The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion.					Coventry was entitled to convert all or any amount of the this note into shares of the Company''s common stock (the ''''Common Stock'''') at a conversion price (''''Conversion Price'''') for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date.
Debt Conversion, Converted Instrument, Shares Issued					7,000,000				18,737,894						8,672,090
Fair Value, Option, Changes in Fair Value, Gain (Loss)												21,789
Gains (Losses) On Extinguishment Of Debt	$ 0	$ 0	$ (213,090)	$ 0								$ 213,090

XML

SUBSEQUENT EVENTS (Details)	9 Months Ended
	Sep. 30, 2012
October Issuance [Member] | Marketing Services [Member]
Stock Issuable During Period For Services	15,100,000
October Issuance [Member] | Employees and Directors [Member]
Stock Issued During Period, Shares, New Issues	24,000,000
October Issuance [Member] | Vendor [Member]
Stock Issued During Period, Shares, Issued For Services	18,500,000
October Issuance [Member] | Notes Payable [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities	33,916,733
October Issuance [Member] | Investor [Member]
Stock Issued During Period, Shares, Issued For Cash	38,400,000
November Issuance [Member] | Loan Holders [Member]
Stock Issuable During Period For Loan Holders	4,000,000

XML

SUBSEQUENT EVENTS (Tables)

9 Months Ended

Sep. 30, 2012

Subsequent Events [Abstract]

Schedule of Subsequent Events [Table Text Block]

Other Subsequent Issuances

Description	Month of Issuance		Number of Shares
Shares issued upon conversion of notes payable		October		33,916,733
To our Directors and employees		October		24,000,000
To vendors as satisfaction for 2012 services and materials		October		18,500,000
To ten investors for cash of $.01 per share (warrants to purchase our common stock for $0.10 per share were also issued – the warrants expire on December 13, 2014)		October		38,400,000
Shares issuable under five separate agreements for marketing services		October		15,100,000
Shares issuable to two loan holders		November		4,000,000